You are here

B-RAF

.

BRAF is mutated in 36.48% of melanoma patients with BRAF V600E present in 22.85% of all melanoma patients 

BRAF V600E is an inclusion criterion in 56 clinical trials for melanoma, of which 33 are open and 23 are closed. Of the trials that contain BRAF V600E and melanoma as inclusion criteria, 1 is early phase 1 (1 open), 18 are phase 1 (8 open), 12 are phase 1/phase 2 (10 open), 22 are phase 2 (12 open), and 3 are phase 3 (2 open) 

Dabrafenib, vemurafenib, binimetinib, encorafenib, cobimetinib, and trametinib are currently approved for use in patients with BRAF V600E in melanoma 

Dabrafenib, trametinib, and vemurafenib are the most frequent therapies in trials for melanoma that contain BRAF V600E

BRAF is mutated in 17.59% of thyroid gland carcinoma patients with BRAF V600E present in 16.58% of all thyroid gland carcinoma patients 

BRAF V600E is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) 

Vemurafenib is the most frequent therapy in trials for thyroid gland carcinoma that contain BRAF V600E 

BRAF is mutated in 16.26% of thyroid gland adenocarcinoma patients with BRAF V600E present in 13.01% of all thyroid gland adenocarcinoma patients 

BRAF V600E is an inclusion criterion in 2 clinical trials for thyroid gland adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF V600E and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (1 open)

BRAF is mutated in 6.57% of cancer patients with BRAF V600E present in 4.38% of all cancer patients 

BRAF V600E is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain BRAF V600E and cancer as inclusion criteria, 2 are phase 1 (1 open)